…
Diagnamed Holdings Corp. engages in the development and commercialization of AI healthcare solutions. The company focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It has a collaboration agreement with EIREX for the development and commercialization of EIREX's novel modular carbon-free technology that extracts hydrogen from water. Diagnamed Holdings Corp. is headquartered in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Diagnamed Holdings Corp appears to be a healthcare company focused on medical diagnostics, though public disclosure and detailed filings are limited. Its long-term growth may depend on broader demand for diagnostic services, adoption of new testing technologies and successful geographic or product expansion. Investors may find exposure to small-cap healthcare upside attractive if the company can demonstrate clinical validation and commercial traction.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
| Income before tax | -1.40M | -0.50M | -1.28M | -1.13M |
| Net income | -1.40M | -0.50M | -1.28M | -1.13M |
| Selling general administrative | 0.61M | 0.43M | 0.82M | 0.57M |
| Operating income | -1.49M | -0.74M | -1.25M | -1.14M |
| Interest income | 0.00M | 0.01M | 0.01M | 0.00M |
| Net interest income | 0.00M | 0.01M | 0.01M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.49M | 0.74M | 1.25M | 1.14M |
| Total other income expense net | 0.08M | 0.23M | -0.03M | 0.00M |
| Net income from continuing ops | -1.40M | -0.50M | -1.28M | -1.13M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
| Total assets | 0.22M | 0.20M | 0.66M | 1.62M |
| Total liab | 0.67M | 0.47M | 0.43M | 0.37M |
| Total stockholder equity | -0.45M | -0.27M | 0.24M | 1.25M |
| Capital stock | 4.28M | 3.57M | 3.57M | 3.17M |
| Retained earnings | -6.26M | -4.86M | -4.36M | -3.08M |
| Cash | 0.18M | 0.16M | 0.61M | 1.57M |
| Total current liabilities | 0.67M | 0.47M | 0.43M | 0.37M |
| Total current assets | 0.22M | 0.20M | 0.66M | 1.62M |
| Net receivables | 0.02M | 0.03M | 0.06M | 0.05M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
| Total cash from financing activities | 0.36M | 0.00M | 0.10M | 0.00M |
| Net income | -1.40M | -0.50M | -1.28M | -1.13M |
| Change in cash | 0.02M | -0.44M | -0.96M | -0.79M |
| Begin period cash flow | 0.16M | 0.61M | 1.57M | 2.36M |
| End period cash flow | 0.18M | 0.16M | 0.61M | 1.57M |
| Total cash from operating activities | -0.34M | -0.44M | -1.07M | -0.79M |
| Issuance of capital stock | - | - | - | 0.00M |
| Change to account receivables | 0.01M | 0.02M | -0.01M | -0.01M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.35M | 0.27M | 0.15M | 0.21M |
| Stock based compensation | 0.30M | 0.00M | 0.01M | 0.14M |
| Other non cash items | 0.52M | - | - | - |
| Free cash flow | -0.34M | -0.44M | -1.07M | -0.79M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| DMED Diagnamed Holdings Corp. |
-0.01 14.29% |
0.03 | - | - | - | 10.74 | -1.43 |
| AIDR Rocket Doctor AI Inc |
-0.01 1.06% |
0.47 | - | - | 1671.77 | 6.46 | -0.39 |
| NARA Pangenomic Health Inc. |
- -% |
0.30 | - | - | - | 5.38 | -0.11 |
| AIML AI/ML Innovations Inc |
- -% |
0.04 | - | - | 70.85 | 35.17 | -3.59 |
| UDOC UniDoc Health Corp. |
0.01 11.11% |
0.05 | - | - | 10.64 | 668.99 | -9.56 |
Diagnamed Holdings Corp. engages in the development and commercialization of AI healthcare solutions. The company focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It has a collaboration agreement with EIREX for the development and commercialization of EIREX's novel modular carbon-free technology that extracts hydrogen from water. Diagnamed Holdings Corp. is headquartered in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Andre Turmel | Independent Executive Chairman | NA |
| Mr. John Karagiannidis | President, CEO & Director | NA |
| Mr. Edward Low | Chief Financial Officer | NA |
| Mr. Andrew Newbury CPA | Corporate Secretary | NA |
| Mr. Edward Low | Interim Chief Financial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.